PASTA: Parasternal vs. Sternotomy Approach for Conventional Aortic Valve Replacement
Study Details
Study Description
Brief Summary
Prospective randomized study comparing aortic valve replacement using parasternal or sternotomy access with regard to quality of life and systemic inflammatory reaction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The classic surgical treatment of aortic stenosis is valve replacement through complete midline opening of the breastbone (median sternotomy) and use of cardiopulmonary bypass (CPB). Risks of this procedure are related to both the surgical approach and the use of CPB. Using minimally invasive approaches in non-cardiac patients (e.g laparoscopy) resulted in reduced postoperative inflammatory response when compared to patients undergoing the same procedures carried out with a conventional "open" technique. Minimally invasive surgical approaches in which the sternum is partially opened (partial sternotomy) or not opened at all (parasternal access) have thus far shown similar procedure related mortality and lower incidence of perioperative complications, despite longer CPB times. Our single center experience thus far suggests superiority of parasternal aortic valve replacement (O/E ratio of 0.19 over the last 2 years), as well as a reduced postoperative inflammatory response (as measured by lower CRP (C reactive protein ) levels taken 6 hours post-surgery). However, these data have several confounders and there is currently no prospective randomized trial addressing this topic. We therefore conduct a randomized comparison of parasternal versus classic sternotomy aortic valve replacement. Based on our previous experience, we expect very low mortality risk in both groups (expected ≤ 1%). The primary endpoint is therefore quality of life assessed using the SF-36 (Short Form) health survey questionnaire. This approach is similar to other current large multicenter trials. In order to address the impact of reduced surgical trauma on inflammatory response; we will quantify an established panel of inflammatory markers (PCT, CRP, interleukin 6) and use bio-banking to allow for further in depth analysis later on. Standardized clinical endpoints will be analyzed as additional secondary parameters. Power analysis determined a number of 50 patients allocated to 2 equal groups to achieve a power of 80%. The parasternal approach is expected to be superior when compared to sternotomy in both the primary and some, if not most, secondary endpoints. We expect our study to become an important milestone for decision-making in the treatment of aortic stenosis. Patients currently fear sternotomy, but the less invasive transcatheter valve implantation appears to be limited by inferior long-term outcome. The parasternal, sternotomy-sparing, classic aortic valve replacement is therefore an attractive therapeutic alternative. Our investigation in relation to systemic inflammatory response will further shed light on the underlying mechanisms explaining differences in clinical outcomes.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Sternotomy AVR Aortic valve replacement due to sternotomy |
Procedure: Aortic valve replacement due to sternotomy
conventional surgery of aortic stenosis
|
| Active Comparator: Mini AVR Aortic valve replacement due to parasternal right anterior mini-thoracotomy |
Procedure: Aortic valve replacement due to parasternal right anterior mini-thoracotomy
surgery of aortic stenosis in minimally invasive technique
|
Outcome Measures
Primary Outcome Measures
- Quality of life - physical function [30 days after surgery]
Comparison of the physical quality of life between the two groups 30 days after surgery using the physical function score of the 36-Item Short Form Health Survey (SF-36). The physical function score is a scale from 0 (poor physical function) to 100 (excellent physical function, with an average score of 50. It includes items that assess physical functioning, bodily pain, physical role functioning, vitality, and generaly health perceptions.
Secondary Outcome Measures
- Inflammatory markers: Procalcitonin, C-reactive protein, Interleukin-6 [During the first 48 hours after surgery]
Plasma profiles of inflammatory biomarkers at defined time points in the course of the surgical intervention (baseline, before introduction of CPB, 1 hour after introduction of CPB, disconnection of CPB, 6, 24 and 48 hours post-surgery)
- Quality of Life - mental function [30 days after surgery]
Comparison of the mental quality of life between the two Groups 30 days after surgery using the mental component score of the 36-Item Short Form Health Survey (SF-36). The mental function score is a scale from 0 (poor mental quality of life) to 100 (excellent mental quality of life), with an average score of 50. It includes items that assess vitality, general health perceptions, emotional role functioning, social role functioning, and mental health.
- Duration of the Operation [During the aortic valve replacement surgery]
Comparison of the average duration of operation between the groups
- Duration of cardiopulmonary bypass [During the aortic valve replacement surgery]
Comparison of the average duration of cardiopulmonary bypass between the groups
- Duration of aortic clamping [During the aortic valve replacement surgery]
Comparison of the average duration of aortic clamping between the two groups
- Major Adverse Cardiac and Cerebrovascular Events (MACCE) [From the time of surgery until the patient is discharged from hospital, an average of 7 days]
A composite endpoint of mortality, myocardial infarction, urgent revascularization, stroke and major bleeding
- Blood transfusion [From the time of surgery until the patient is discharged from hospital, an average of 7 days]
A comparison of the number of transfusions between the groups
- Rethoracotomy for bleeding [From the time of surgery until the patient is discharged from hospital, an average of 7 days]
The incidence of rethoracotomy for bleeding after surgery
- Post-operative pain [From the time of surgery until the patient is discharged from hospital, an average of 7 days]
Measurement of patient's subjective assessment of their pain after surgery using a visual scale
- Duration of mechanical ventilation [Measured from the time of arrival in the Intensive Care Unit until the time patients are extubated, an average of 12 hours]
Comparison of the average duration of mechanical ventilation between the groups
- Length of ICU stay [From the time of surgery until the patient is discharged from hospital, an average of 30 days]
Comparison of the average number of days spent in Intensive Care Unit between the two groups
- Length of hospital stay [From the time of surgery until the patient is discharged from hospital, an average of 30 days]
Comparison of the average number of days spent in hospital between the groups
- Atrial fibrillation [From the time of surgery until the patient is discharged from hospital, an average of 7 days]
Incidence of new-onset atrial fibrillation after cardiac surgery
- Wound infection [During the first 30 days after surgery]
Incidence of wound infections
- Mortality [During the first 30 days after surgery]
intra- and postoperative mortality
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Indication for elective isolated aortic valve replacement
-
Anatomical suitability for both sternotomy and parasternal access
-
Age ≥ 18
-
Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
Exclusion Criteria:
-
Planned simultaneous cardiac surgery interventions (Mitral valve surgery, tricuspid valve surgery, CABG, Pacemaker or defibrillator implantation, Pulmonalvenenisolation, Maze, closure of left atrial appendage , patent foramen ovale or atrial septal defect closure)
-
Acute myocardial infarction within 4 weeks, coronary heart disease
-
Acute endocarditis
-
TIA or stroke within 6 months prior to the procedure
-
Pregnant or breast-feeding women
-
Renal failure requiring dialysis
-
Ejection fraction ≤ 30%
-
Re-operation
-
Disease with a life expectancy < 2 years
-
Therapy with glucocorticoids or immunosuppressants
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UKJ | Jena | Thueringen | Germany | 07747 |
Sponsors and Collaborators
- Jena University Hospital
- The German Heart Foundation
Investigators
- Principal Investigator: Sophie Tkebuchava, MD, University Hospital Jena
- Principal Investigator: Torsten Doenst, MD, University Hospital Jena
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PASTA-UKJ